Corrigendum: Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: An expert consensus (CNS Spectrums (2018) 23:6 (402-413) DOI: 10.1017/S1092852918001359)

Kevin J. Black, Henry Nasrallah, Stuart Isaacson, Mark Stacy, Rajesh Pahwa, Charles H. Adler, Gustavo Alva, Jeffrey W. Cooney, Daniel Kremens, Matthew A. Menza, Johnathan M. Meyer, Ashwin A. Patkar, Tanya Simuni, Debbi A. Morrissette, Stephen M. Stahl

Research output: Contribution to journalComment/debate

Abstract

In the original publication "Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus," by Black et al. (2018), the authors regret the errors found in Table 1; Boxes 1, 3, and 4; and Figure 1. The correct Table 1, Boxes 1, 3, and 4, and Figure 1 are given below. (Table Presented). (Figure Presented). In addition, the authors would like to make the following text corrections and clarifications: Page 405: • The MDS EBM was published in 2011. Page 406: • The doses in the early phase 2b/3 study were placebo, 8.5, and 34 mg/d. • The P-value for the hallucination and delusions subscales was 0.0012. • Sleep quality, caregiver burden, etc. were exploratory outcomes. Page 407: • The QT prolongation for pimavanserin is 5-8 msec. The original publication has been corrected to reflect these changes.

Original languageEnglish (US)
Pages (from-to)574-575
Number of pages2
JournalCNS Spectrums
Volume24
Issue number5
DOIs
StatePublished - Oct 1 2019

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Corrigendum: Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: An expert consensus (CNS Spectrums (2018) 23:6 (402-413) DOI: 10.1017/S1092852918001359)'. Together they form a unique fingerprint.

  • Cite this

    Black, K. J., Nasrallah, H., Isaacson, S., Stacy, M., Pahwa, R., Adler, C. H., Alva, G., Cooney, J. W., Kremens, D., Menza, M. A., Meyer, J. M., Patkar, A. A., Simuni, T., Morrissette, D. A., & Stahl, S. M. (2019). Corrigendum: Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: An expert consensus (CNS Spectrums (2018) 23:6 (402-413) DOI: 10.1017/S1092852918001359). CNS Spectrums, 24(5), 574-575. https://doi.org/10.1017/S1092852919000932